bioAffinity Tech Files 8-K: Regulation FD Disclosure on March 26, 2026

Ticker: BIAF · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001712762

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, disclosure, corporate-action

TL;DR

**bioAffinity Technologies just dropped an 8-K with new info, watch for details in EX-99.1.**

AI Summary

bioAffinity Technologies, Inc. filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are publicly disclosing information that was not previously made public. This filing includes an exhibit, EX-99.1, which often contains a press release or investor presentation. For investors, this matters because it signals new, potentially material information about the company's operations, financial health, or strategic direction is being shared, which could influence stock performance.

Why It Matters

This filing indicates bioAffinity Technologies is making new, important information public, which could impact investor perception and the company's stock price.

Risk Assessment

Risk Level: medium — The risk is medium because the specific content of the disclosure (EX-99.1) is not detailed in the 8-K itself, so the impact on the company is currently unknown.

Analyst Insight

A smart investor would review the EX-99.1 exhibit immediately to understand the specific nature of the Regulation FD disclosure and assess its potential impact on bioAffinity Technologies, Inc.'s future performance and stock valuation.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by bioAffinity Technologies, Inc.?

The primary purpose of this 8-K filing is to disclose information under Item 7.01, Regulation FD Disclosure, meaning bioAffinity Technologies, Inc. is making public information that was not previously public.

When was this 8-K filing submitted and accepted by the SEC?

This 8-K filing was submitted and accepted by the SEC on March 26, 2026, with an acceptance time of 08:00:31.

What specific exhibit is included in this 8-K filing that likely contains the new disclosure?

The specific exhibit included in this 8-K filing that likely contains the new disclosure is EX-99.1, which is listed as 'ex99-1.htm' and has a size of 20042 bytes.

What is the business address of bioAffinity Technologies, Inc. as listed in the filing?

The business address of bioAffinity Technologies, Inc. is 3300 NACOGDOCHES ROAD SUITE 216, SAN ANTONIO TX 78217, with a phone number of 210-698-5334.

Under which SIC code does bioAffinity Technologies, Inc. operate, according to this filing?

According to this filing, bioAffinity Technologies, Inc. operates under SIC code 8731, which is described as 'Services-Commercial Physical & Biological Research'.

Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2026-03-26 08:00:31

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 26, 2026 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing